Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Aims: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are employed extensively in the management of type 2 diabetes and obesity. However, there is a paucity of real-world data on their safety and tolerability for metabolic and nutritional adverse events in large sample populations. This study aimed to analyse the metabolic and nutritional safety signatures of different GLP-1 RAs by exploring the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). Methods: AEs data were extracted from the FDA Adverse Event Reporting System database for each GLP-1 RA from the time of its launch until the second quarter of 2023. The reported odds ratio (ROR), proportional reporting ratio (PRR), Empirical Bayesian Geometric Mean and Bayesian Confidence Propagation Neural Network were employed to identify AE signals. Results: A system organ class of metabolism and nutrition disorders was employed to filter AE reports, resulting in the identification of 10,450 reports for exenatide, 2,860 reports for liraglutide, 240 reports for albiglutide, 4,847 reports for dulaglutide, 2,905 reports for semaglutide, 1,089 reports for tirzepatide, and 13 reports for lixisenatide. Semaglutide (ROR, 3.34; 95%CI, 3.22), liraglutide (ROR, 2.78; 95%CI, 2.69), and exenatide (ROR, 2.15; 95%CI, 2.11) were associated with metabolism and nutrition disorders. The number of AE signals detected were as follows: albiglutide (n = 1), lixisenatide (n = 2), tirzepatide (n = 11), exenatide (n = 12), liraglutide (n = 16), semaglutide (n = 20), dulaglutide (n = 22). Dehydration was the most frequent AE contributing to serious outcomes for liraglutide (n = 318, 23.93%), dulaglutide (n = 434, 20.90%), semaglutide (n = 370, 25.10%) and tirzepatide (n = 70, 32.86%). The time to onset (TTO) of AE was statistically different between exenatide and the other GLP-1 RAs ( p < 0.001), and the Weibull parameters for dehydration for liraglutide, dulaglutide, and semaglutide analyses all showed an early failure-type profile. Conclusion: Our study suggests that exenatide, liraglutide, and semaglutide are more susceptible to metabolic and nutritional AEs than other GLP-1 RAs. Liraglutide, dulaglutide, semaglutide, and tirzepaptide’s potential to induce dehydration, necessitates special attention. Despite certain deficiencies, GLP-1 RAs have considerable potential for the treatment of eating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Common side effects of anti-obesity medications are abdominal pain, diarrhea, and nausea [87,103,104].”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [104]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While mild nutritional ketosis can occur during energy restriction and is generally well tolerated, more severe ketone accumulation, including diabetic ketoacidosis (DKA) and euglycemic DKA, has been reported in rare cases among individuals using GLP-1Ras [44].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings are consistent with a 2023 meta-analysis showing that liraglutide was associated with a significantly increased odds of ketosis in patients with type 1 diabetes (OR 1.8; 95% CI, 1.1–2.8) [49].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additional considerations for some medications involve associations with hypotension, hypoglycemia, (incretins), and CNS depression, all of which warrant safety precautions for any altered level of consciousness such as avoiding exercise alone and taking falls precautions [87,104].”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [104]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Often, patients on any obesity medication, but particularly incretin medications, are at risk for a low oral intake of fluids and solid food, predisposing to dehydration, and patients, particularly those engaging in vigorous or intense physical activity, should be encouraged to hydrate and eat water-rich foods [104,105].”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [104]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication
Hudson, J. I., Hiripi, E., Pope, H. G., & Kessler, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.040 · Cited by 4,973
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“GLP-1RAs increase satiety, reduce food intake, and delay gastric emptying (Drucker, 2018; Novikoff and Müller, 2024).”
BackgroundDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Evans, S. J. W., Waller, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,802
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Szarfman, A., Machado, S. G., & O??Neill, R. T. (2002) · Drug Safety · doi:10.2165/00002018-200225060-00001 · Cited by 700
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Sex differences in the physiology of eating
Asarian, L., & Geary, N. (2013) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00446.2012 · Cited by 513
He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., Xu, L., Li, W., & Zhang, H. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0338 · Cited by 356
Self-citation
Cited by
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., et al. (2025) · Nutrients · doi:10.3390/nu17142382 · Cited by 29
“…obesity medication, but particularly incretin medications, are at risk for a low oral intake of fluids and solid food, predisposing to dehydration, and patients, particularly those engaging in vigorous or intense physical activity, should be encouraged to hydrate and eat water-rich foods [104,105].”
Al‐Soleiti, M., Leung, J. G., Mubaydeen, T., Markota, M., Abulseoud, O. A., Singh, B., & Sola, C. L. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002090 · Cited by 24
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes
Sheth, K., Kim, S., Porterfield, L. R., Virani, S. S., Wadhwani, S., & Vaughan, E. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01319-6 · Cited by 21
GLP-1 Receptor Agonists – Good for Body Weight, Bad for Micronutrient Status?
Kerlikowsky, F., Krämer, K., Eggersdorfer, M., & Hahn, A. (2025) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2025.107587 · Cited by 18
“Long et al. [46] observed that the occurrence of nutritional disturbances such as food craving, food aversion, appetite disturbances, and reduced fluid intake differed between the GLP-1 RA used, showing that exenatide, liraglutide, and semaglutide are more likely to be associated with nutritional…”
Triplett, J. D., Pinto, M. V., Young, N. P., Staff, N. P., Marathe, C. S., Horowitz, M., Pinto, C. A., Laughlin, R. S., Shouman, K., Berini, S. E., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213916 · Cited by 18
Zhang, J., Wang, X., & Zhou, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1471615 · Cited by 17
Al-Najim, W., Raposo, A., BinMowyna, M. N., & le Roux, C. W. (2025) · Nutrients · doi:10.3390/nu17111934 · Cited by 16
“While mild nutritional ketosis can occur during energy restriction and is generally well tolerated, more severe ketone accumulation, including diabetic ketoacidosis (DKA) and euglycemic DKA, has been reported in rare cases among individuals using GLP-1Ras [44].”
InfluentialGu, S. (2026) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s556918 · Cited by 15
Glucagon-Like Peptide-1 Receptor Agonists in Psychiatry: A Pharmacoepidemiological Scoping Review
Volkow, N. D., & Xu, R. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.03.1002 · Cited by 14
Huang, X., Wu, M., Huang, B., & Zhang, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1509947 · Cited by 12
Malnutrition with use of GLP-1 agonists is an underestimated real world harm
Fallows, E. (2025) · BMJ · doi:10.1136/bmj.r1512 · Cited by 12
Li, M., Hu, J., Chin, Y. H., Chew, H. S. J., & Wang, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1681965 · Cited by 9
Zahir, A. T., Collins, D. P., Ip, S., Samghabadi, P., Douglas, V. C., & LaHue, S. C. (2025) · BMC Neurology · doi:10.1186/s12883-025-04540-7 · Cited by 9
Dobbie, L. J., Tolvanen, L., Alves, D., Baker, J. L., Bez, N. S., Birney, S., Bogl, L. H., Brown, A., Bullo, M., Clare, K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00122-1 · Cited by 8
Duan, Z., Wei, K., Xue, Z., Zhou, J., Yang, S., Ma, S., Jin, J., & Li, L. (2025) · PubMed · doi:10.48550/arxiv.2504.04346 · Cited by 8
Micronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity
Koceva, A., Janež, A., Pečko, T., & Jensterle, M. (2026) · Nutrients · doi:10.3390/nu18040677 · Cited by 7
Ponzo, V., Vitale, M., Bo, S., Broglio, F., Goitre, I., & Cioffi, I. (2025) · Nutrients · doi:10.3390/nu17213318 · Cited by 7
Salvatore, M., Zhang, B., Tang, H., Lu, Y., Zhang, D., Zhou, T., Lu, Y., Amaro, A., Ritchie, M. D., & Chen, Y. (2025) · medRxiv · doi:10.1101/2025.06.03.25328908 · Cited by 4
Ezenekwe, L., & Newberry, C. A. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.70074 · Cited by 3
Liu, L., Chen, J., Zhang, X., Zhu, S., Dai, T., Wu, Q., & Fang, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02064-1 · Cited by 3
Navigating the benefits and harms of GLP-1 and GLP-1/GIP agonists in obesity
O'Connor, R. G. (2026) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2025.000039 · Cited by 2
Analysis and mining of adverse events associated with vorapaxar: A FAERS database-based study
Zhang, H., Lin, M., Song, C., Nan, Z., Zhao, D., & Fu, Y. (2026) · PLoS ONE · doi:10.1371/journal.pone.0340893 · Cited by 2
GLP-1 guidelines amid an obesity epidemic: a poor fit for the Global South
Shrisunder, R., & Karmarkar, V. (2026) · Archives of Public Health · doi:10.1186/s13690-026-01883-6 · Cited by 2
Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists
Lixi, F., Troisi, M., Calabresi, V., Giagoni, A., Rossi, C., Timofte-Zorila, M.-M., Tarași, T.-C., Vitiello, L., Tomi, M.-I., Gheorghe, A. G., et al. (2026) · Vision · doi:10.3390/vision10020029 · Cited by 3
Al-Burak, S. A., Suleiman, A., Voznyy, V., Elganga, M., Zajner, C., Juncal, V., Sheidow, T., & Malvankar‐Mehta, M. S. (2026) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2026.05.010 · Cited by 2
Khani, E., Asham, H., Rezabakhsh, A., Babaei, S., & Entezari‐Maleki, T. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70248 · Cited by 2
Song, N., Xi, X., Zhang, K., Li, Z., Kuan, Y., & Pei, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07338-w · Cited by 1
Senthilkumar, A., Hays, H. L., Kistamgari, S., Rine, N. I., Rhodes, A. L., Gaw, C. E., & Smith, G. A. (2026) · Journal of Medical Toxicology · doi:10.1007/s13181-026-01128-6 · Cited by 1
Zhao, G., Ma, N., Yang, Y., Yang, A., & Gao, B. (2026) · British Journal of Ophthalmology · doi:10.1136/bjo-2026-329598 · Cited by 1
Self-citationRen, L., Zhang, Y., Fang, F., & Ma, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71303 · Cited by 1
Arslan, T. (2026) · Endocrine · doi:10.1007/s12020-026-04840-z · Cited by 1
Cheng, F., Niu, X., Wang, Y., Yang, F., Yang, K., & Li, W. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01744-2 · Cited by 1
Park, S. J., Rosen, R. L., Muñoz‐Vergara, D., Manson, J. E., Yeh, G. Y., Wayne, P. M., & Sesso, H. D. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5363323
Chen, H., Zhang, X., Chen, D., Jiang, X., & Yu, C. (2025) · Medicine · doi:10.1097/md.0000000000046304
Einfluss von GLP-1-Analoga auf die Mikronährstoffversorgung
Kerlikowsky, F., Krämer, K., Eggersdorfer, M., & Hahn, A. (2025) · Ernährung & Medizin · doi:10.1055/a-2492-9615
GLP-1 receptor agonists and depression in obesity: current evidence
Głaz, D., Deska, Ł., Zysiak, S., Głaz, M., Kamińska, N., Zaguła, J., Sołtys, W., Kosmecki, C., Stronczyński, M., & Wicha, K. (2026) · Archiv Euromedica · doi:10.35630/2026/16/iss.1.005
CROSS-SPECIALTY CARE IN DIABETIC RETINOPATHY : ENDOCRINOLOGY MEETS OPHTHALMOLOGY
Ali, H. (2025) · Gomal Journal of Life Sciences · doi:10.66406/gjls0141
Safety of glucagon-like peptide-1 agonists: data from the Russian National pharmacovigilance system
Gomon, Y. М., Александровна, М. Е., Колбин, А. С., & Горелов, К. В. (2026) · Real-World Data & Evidence · doi:10.37489/2782-3784-myrwd-092
Bhavsar, D. (2025) · International Journal of Basic and Applied Sciences · doi:10.14419/n99q9v48
Basso, A. L. F., Falcetti, E. M., Coelho, R. P., Maia, G. A., de Oliveira, L. R. B., Prates, F. F., & TREPICHE, S. D. (2026) · Research Society and Development · doi:10.33448/rsd-v15i6.51184
de Carvalho, M. D., Barros, M. S. F., Câmara, T. D. A. V., Pereira, L. C. S., Borges, E. C. A., Dias, J. F., Silva, M. L. F., Costa, E. P., Verde, M. D. S. F., & Nunes, G. S. (2026) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e23909.2026
GUIMARÃES, K. D. S., CARVALHO, A. C. G. D., LEMOS, M. V. M. D., de Araújo, G. D. F. L., SERRA, I. G. S., OLIVEIRA, L. S., & Ribeiro, R. M. (2026) · doi:10.63319/scied-978-65-979059-0-4_039 · Cited by 1
Chimango, R., & Dash, S. (2026) · International Journal of Pharmaceutical Research and Development · doi:10.33545/26646862.2026.v8.i7b.412
RISCOS TOXICOLÓGICOS DO USO OFFLABEL DE FÁRMACOS HORMONAIS E ANTIDIABÉTICOS PARA PERDA DE PESO
Souza, A. G. D., & Hott, S. C. (2026) · REVISTA MULTIDISCIPLINAR INTEGRADA - REMI · doi:10.61164/h28tvw13
OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD
Li, Z., Song, J., Ma, K., Tang, S., Wang, S., Ji, W., Lu, C., Zhang, T., Zheng, H., Zheng, X., et al. (2026) · Advanced Science · doi:10.1002/advs.77451
Mikołajuk, A., Mallah, R., Kozdroń, D. J., Nieścioruk, M. W., Szczepańska, P., Kowalski, J., Dutkiewicz, D., & Yarbou, A. E. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5581
Hulu, A. P. H., Zebua, W. I., Halawa, F., & Sarumaha, J. H. (2026) · Journal of Intelligent Computing & Health Informatics · doi:10.26714/jichi.v7i2.22677
Kwaśny, A., Słoma-Krześlak, M., Kostelecki, G., Rychter, A. M., Brzegowy, M., Jeziorek, M., Kręgielska-Narożna, M., Lange, E., Boniecka, I., Prejbisz, A., et al. (2026) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/235937
Thawkar, S. A., Singare, S. R., & Sakle, N. S. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.105169
Research on Adverse Drug Reaction Signal Mining for Diabetes under Large-Scale Medical Data
张鑫尧 (2026) · International Conference on Biomedical and Intelligent Systems (IC-BIS) · doi:10.1145/3841905.3841999
Stocker, G., Kazeminasab, F., Nejatkhah, F., Zarreh, M., Mirahmadi, N., Bagheri, R., Messenburger, G. P., Delpino, F. M., Kirwan, R., & Santos, H. O. (2026) · Advanced Exercise and Health Science · doi:10.1016/j.aehs.2026.09.003
Beyond the Scale: The Evolving Role of GLP1 Receptor Agonists in Modern HIV Care
Mourad, N. F., Hammoud, R., Tsioutis, C., & Alon-Ellenbogen, D. (2026) · Metabolites · doi:10.3390/metabo16110894
Metadata
- Authors
- He, L., Li, Q., Yang, Y., Li, J., Luo, W., Huang, Y., & Zhong, X.
- Affiliations
- Southwest Medical University (CN)
- Corresponding author
- Huang, Yilan
- Zhong, Xiaoyan
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2024-07-08
- Volume
- 15
- Pages
- 1416985-1416985
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC11260617
- OpenAlex
- W4400430779
- Cited by
- 40
- References
- 59
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 1
- FWCI
- 9.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, adverse event signals, metabolic side effects, dehydration, liraglutide, semaglutide, dulaglutide, exenatide, tirzepatide, albiglutide, lixisenatide, type 2 diabetes, obesity, drug safety, FDA Adverse Event Reporting System, pharmacovigilance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.